ArticleNeurology2022
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Review
- Breakthroughs and challenges of CAR-T cell therapy in treating hematologic malignancies of the central nervous system.Blood science (Baltimore, Md.) · 2026Review
- The development of CAR T cells for patients with CNS malignancies.Nature reviews. Clinical oncology · 2026Review
- Advances in CAR-T therapy for central nervous system lymphoma.Frontiers in immunology · 2026Review
- CAR T-cell therapy induced pseudoprogression.Frontiers in immunology · 2026Review
- Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology · 2025Article
- Neuroimaging Findings of CAR T-Cell-Associated Neurotoxicity: A Review.Neurology. Clinical practice · 2025Review
- Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas.Bone marrow transplantation · 2025Review
- Case Report: CD19 CAR-T therapy induces dual remission in AML-M2b patient with CNS-PTLD and relapse.Frontiers in immunology · 2025Article
- Novel Therapies in Primary Central Nervous System Lymphoma.Clinical pharmacology : advances and applications · 2025Review
- Novel Therapies for Primary Central Nervous System Lymphomas.Current neurology and neuroscience reports · 2024Review
- CAR-T Cells for the Treatment of Central Nervous System Tumours: Known and Emerging Neurotoxicities.Brain sciences · 2024Review
- Advances in CAR-T therapy for central nervous system tumors.Biomarker research · 2024Review
- High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.Blood advances · 2024Article
- CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.Blood advances · 2024Article
- Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.British journal of haematology · 2024Article
- [New treatment strategies for primary lymphoma of the central nervous system].Der Nervenarzt · 2024Review
- Updates of primary central nervous system lymphoma.Therapeutic advances in hematology · 2024Review
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Pigment cell & melanoma research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSecondary CNS involvement in systemic B-cell lymphoma (SCNSL) is difficult to treat and displays dismal clinical outcomes. Chimeric antigen receptor (CAR) T cells emerged as a powerful treatment for systemic lymphoma. We aimed to evaluate whether CAR T cells also represent a safe and effective therapy for SCNSL.
methodsWe retrospectively searched our institutional database for patients with SCNSL treated with CD19-directed CAR T cells.
resultsWe identified 10 cases, including 7 patients with intraparenchymal lesions and 3 patients with leptomeningeal disease. CNS staging at 1 month after CAR T-cell transfusion showed disease response (stable disease, partial response, and complete response) in 7 patients (70%), including 2 cases of long-lasting complete response (20%). One patient developed pseudoprogression, which resolved under steroids. Response of CNS disease was associated with systemic 1-month response. With a median follow-up of 6 months, median overall and systemic progression-free survival was 7 and 3 months, respectively. Neurotoxic symptoms occurred in 6 patients, with 3 patients developing severe neurotoxicity (American Society for Transplantation and Cellular Therapy grade ≥3). DISCUSSION: CAR T cells induce considerable antitumor effects in SCNSL, and CNS response reflects systemic response. Neurotoxicity appears similar to previous reports on patients with lymphoma without CNS involvement. CAR T cells may therefore represent an effective and safe therapy for SCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.